138 related articles for article (PubMed ID: 32139450)
1. Adalimumab as a potential cause of drug-induced thrombocytopaenic microangiopathy.
Falsetti L; Sampaolesi M; Riccomi F; Nitti C
BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32139450
[TBL] [Abstract][Full Text] [Related]
2. Periappendicitis during adalimumab treatment for ileocecal Crohn's disease in a 29-year-old male.
Mizuno S; Nakazawa A; Ogawa A; Hisamatsu T; Hirose S; Tsukada N
Clin J Gastroenterol; 2015 Jun; 8(3):134-7. PubMed ID: 26023062
[TBL] [Abstract][Full Text] [Related]
3. Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol.
Baysal M; Ümit EG; Sarıtaş F; Kodal NS; Demir AM
Balkan Med J; 2018 Sep; 35(5):398-399. PubMed ID: 29687787
[TBL] [Abstract][Full Text] [Related]
4. Asymptomatic choroidal tubercle in a patient with Crohn's disease on adalimumab treatment.
Asensio-Sánchez VM; Díaz-Cabanas L; Martín-Prieto A; Haro-Álvarez B
Arch Soc Esp Oftalmol (Engl Ed); 2018 Mar; 93(3):147-150. PubMed ID: 28743416
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report.
Omura T; Watanabe E; Otsuka Y; Yoshida Y; Kato H; Nangaku M; Miyata T; Oda S
Medicine (Baltimore); 2016 Jul; 95(27):e4104. PubMed ID: 27399110
[TBL] [Abstract][Full Text] [Related]
6. [Tubulointerstitiel nephritis and Crohn's disease, nephrotoxicity or extraintestinal manifestation of Crohn's disease? About a case].
Treffel M; Champigneulle J; Meibody F; Laurain E; Frimat L; Busby-Venner H
Nephrol Ther; 2019 Mar; 15(1):59-62. PubMed ID: 30503098
[TBL] [Abstract][Full Text] [Related]
7. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
Van Steenbergen S; Bian S; Vermeire S; Van Assche G; Gils A; Ferrante M
Aliment Pharmacol Ther; 2017 Apr; 45(7):923-932. PubMed ID: 28164321
[TBL] [Abstract][Full Text] [Related]
8. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary actinomycosis coexisting with intestinal tuberculosis as a complication of adalimumab treatment for Crohn's disease.
Aleric I; Katalinic D; Vcev A; Brinar M
Acta Gastroenterol Belg; 2017; 80(4):544-546. PubMed ID: 29560655
[No Abstract] [Full Text] [Related]
10. Carfilzomib-induced thrombotic microangiopathy. A case report.
Scheggi V; Merilli I; Cesaroni E; Alterini B
J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466
[TBL] [Abstract][Full Text] [Related]
11. Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study.
Orlando A; Renna S; Mocciaro F; Cappello M; Giunta M; Mendolaro M; Mazza M; Rizzuto G; Orlando E; Affronti M; Dimarco M; Di Mitri R; Craxì A; Cottone M
Dig Liver Dis; 2016 Nov; 48(11):1314-1317. PubMed ID: 27578212
[TBL] [Abstract][Full Text] [Related]
12. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
Hyams JS; Dubinsky M; Rosh J; Ruemmele FM; Eichner SF; Maa JF; Lazar A; Alperovich G; Mostafa NM; Robinson AM
Aliment Pharmacol Ther; 2019 Jan; 49(2):155-164. PubMed ID: 30506693
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of adalimumab for Crohn's disease in real clinical practice].
Knyazev OV; Kagramanova AV; Ruchkina IN; Fadeeva NA; Lishchinskaya AA; Boldyreva ON; Zhulina EY; Shcherbakov PL; Orlova NV; Kirova MV; Parfenov AI
Ter Arkh; 2017; 89(2):20-27. PubMed ID: 28281511
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.
Seo H; Ye BD; Song EM; Lee SH; Chang K; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK
Dig Dis Sci; 2017 Oct; 62(10):2882-2893. PubMed ID: 28822006
[TBL] [Abstract][Full Text] [Related]
15. Oxymorphone Induced Thrombotic Microangiopathy Mimicking Atypical Haemolytic Uremic Syndrome.
Gandhi A; Ullah S; Kotadia S; Nasser S
J Ayub Med Coll Abbottabad; 2017; 29(2):360-362. PubMed ID: 28718268
[TBL] [Abstract][Full Text] [Related]
16. Drug induced thrombotic microangiopathy caused by levofloxacin.
Kazi S; Preston GC
J R Coll Physicians Edinb; 2018 Jun; 48(2):127-129. PubMed ID: 29992202
[TBL] [Abstract][Full Text] [Related]
17. Severe Attack of Henoch-Schönlein Purpura With Neurological Involvement During Adalimumab Treatment for Crohn's Disease.
Condamina M; Diaz E; Jamart C; Loget J; Durlach A; Salmon JH; Cadiot G; Viguier M
J Crohns Colitis; 2020 May; 14(4):538-542. PubMed ID: 31589303
[TBL] [Abstract][Full Text] [Related]
18. IgA nephropathy onset in a Crohn's disease patient treated with Adalimumab.
Bruzzese V; Lorenzetti R; Rosa M; Di Giulio S; Hassan C; Costas G; Zullo A
Minerva Gastroenterol Dietol; 2016 Jun; 62(2):223-4. PubMed ID: 27091038
[No Abstract] [Full Text] [Related]
19. Early Differentiation of Shiga Toxin-Associated Hemolytic Uremic Syndrome in Critically Ill Adults With Thrombotic Microangiopathy Syndromes.
Joseph A; Rafat C; Zafrani L; Mariani-Kurkdjian P; Veyradier A; Hertig A; Rondeau E; Mariotte E; Azoulay E
Crit Care Med; 2018 Sep; 46(9):e904-e911. PubMed ID: 29979220
[TBL] [Abstract][Full Text] [Related]
20. Antineutrophil cytoplasmic antibodies associated vasculitis in patient with Crohn's disease treated with adalimumab.
Martín Varas C; Heras M; Saiz A; Coloma R; Calle L; Callejas R; Molina Á; Rodríguez MA; Fernández-Reyes Luis MJ
Nefrologia; 2017; 37(5):560-561. PubMed ID: 28946973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
